Literature DB >> 8106150

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

B Gomez-Mancilla1, P J Bédard.   

Abstract

A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into chorea.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106150     DOI: 10.1097/00002826-199310000-00004

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  41 in total

1.  Chronic high-frequency stimulation therapy in hemiparkinsonian rhesus monkeys using an implanted human DBS system.

Authors:  Yiqun Cao; Peihao Yin; Xiaowu Hu; Yiqin Ge; Xiaoping Zhou
Journal:  Neurol Sci       Date:  2012-05-24       Impact factor: 3.307

Review 2.  Therapy for Parkinson's disease: what is in the pipeline?

Authors:  Fabrizio Stocchi
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.

Authors:  M J Jackson; T Swart; R K B Pearce; P Jenner
Journal:  J Neural Transm (Vienna)       Date:  2014-02       Impact factor: 3.575

Review 4.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

5.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

Review 6.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

Review 7.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 8.  Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Authors:  Thomas N Chase; Francesco Bibbiani; Justin D Oh
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

10.  The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.

Authors:  Antti Haapalinna; Tiina Leino; Esa Heinonen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.